Neumora Therapeutics (NMRA) Other financing activities (2022 - 2025)
Neumora Therapeutics (NMRA) posted quarterly Other financing activities of $216000.0 for Q4 2025, down 82.4% year-over-year from $1.2 million in Q4 2024, and up 266.1% quarter-over-quarter from $59000.0 in Q2 2025.
Neumora Therapeutics (NMRA) Other financing activities (2022 - 2025) Analysis & Trends
Neumora Therapeutics' Other financing activities history runs 4 years deep, the most recent figure standing at $216000.0 for Q4 2025.
- In Q4 2025, Other financing activities fell 82.4% year-over-year to $216000.0; the TTM figure through Dec 2025 stood at $275000.0 (down 96.32% YoY), while the FY2025 annual figure was $275000.0, down 96.32% from the prior year.
- Other financing activities for Q4 2025 stood at $216000.0, up from $59000.0 in the prior quarter.
- The five-year high for Other financing activities was $230.0 million in Q4 2023, with the low at $42000.0 in Q4 2022.
- The 4-year median for Other financing activities is $1.2 million (2024), against an average of $21.9 million.
- The sharpest annual moves came in 2023 and 2024: Other financing activities surged 547633.33% in 2023, then slumped 99.47% in 2024.
- Neumora Therapeutics' Other financing activities stood at $42000.0 in 2022, then soared by 547633.33% to $230.0 million in 2023, then plunged by 99.47% to $1.2 million in 2024, then slumped by 82.4% to $216000.0 in 2025.
- Business Quant data shows NMRA's Other financing activities at $216000.0 in Q4 2025, $59000.0 in Q2 2025, and $1.2 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Neumora Therapeutics | 296.45 Mn | 296.45 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 216,000.00 |
| Dec 31, 2025 | 216,000.00 |
| Jun 30, 2025 | 59,000.00 |
| Jun 30, 2025 | 59,000.00 |
| Dec 31, 2024 | 1.23 Mn |
| Dec 31, 2024 | 1.23 Mn |
| Sep 30, 2024 | 1.76 Mn |
| Sep 30, 2024 | 1.76 Mn |
| Jun 30, 2024 | 2.65 Mn |
| Jun 30, 2024 | 2.65 Mn |
| Mar 31, 2024 | 1.85 Mn |
| Mar 31, 2024 | 1.85 Mn |
| Dec 31, 2023 | 230.05 Mn |
| Dec 31, 2023 | 230.05 Mn |
| Sep 30, 2023 | 1.51 Mn |
| Sep 30, 2023 | 1.51 Mn |
| Jun 30, 2023 | 404,000.00 |
| Jun 30, 2023 | 404,000.00 |
| Mar 31, 2023 | 602,000.00 |
| Mar 31, 2023 | 602,000.00 |